Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000646160 | SCV000767918 | uncertain significance | Hereditary spastic paraplegia 39 | 2021-09-01 | criteria provided, single submitter | clinical testing | This sequence change replaces glycine with arginine at codon 792 of the PNPLA6 protein (p.Gly792Arg). The glycine residue is highly conserved and there is a moderate physicochemical difference between glycine and arginine. This variant is not present in population databases (ExAC no frequency). This variant has not been reported in the literature in individuals affected with PNPLA6-related conditions. Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Probably Damaging"; Align-GVGD: "Class C0"). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Gene |
RCV001766388 | SCV001990989 | uncertain significance | not provided | 2019-10-04 | criteria provided, single submitter | clinical testing | In silico analysis, which includes protein predictors and evolutionary conservation, supports that this variant does not alter protein structure/function; Has not been previously published as pathogenic or benign to our knowledge; A different missense change at this residue (G792E) has been reported in the published literature (Synofzik et al., 2014) |
Mayo Clinic Laboratories, |
RCV001766388 | SCV002541489 | uncertain significance | not provided | 2021-10-21 | criteria provided, single submitter | clinical testing |